{"id":"NCT02799082","sponsor":"Biofrontera Bioscience GmbH","briefTitle":"Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis.","officialTitle":"A Randomized, Double-Blind, Phase III Multi-Center Study Evaluating the Safety and Efficacy of BF-200 ALA Versus Placebo in the Treatment of Actinic Keratosis (AK) When Using PDT","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-12","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2016-06-14","resultsPosted":"2017-04-06","lastUpdate":"2017-04-06"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Actinic Keratosis"],"interventions":[{"type":"DRUG","name":"Vehicle","otherNames":[]},{"type":"DRUG","name":"BF-200 ALA","otherNames":["Ameluz"]}],"arms":[{"label":"Vehicle","type":"PLACEBO_COMPARATOR"},{"label":"BF-200 ALA","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of the study was to evaluate the efficacy and safety of BF-200 ALA (Ameluz) used with photodynamic therapy (PDT) in patients suffering from actinic keratosis.","primaryOutcome":{"measure":"Total Patient Clearance Rate 12 Weeks After the Last Photodynamic Therapy (PDT)","timeFrame":"12 weeks after the last photodynamic therapy (PDT), up to 24 weeks","effectByArm":[{"arm":"Vehicle","deltaMin":12.5,"sd":null},{"arm":"BF-200 ALA","deltaMin":66.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["20518784","23252768"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":41},"commonTop":["Application site erythema","Application site irritation","Application site pain","Application site oedema","Application site pruritus"]}}